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Abstract
 
Vaccination with leishmanial Ag and CpG oligodeoxynucleotides (ODN) confers sustained
cellular immunity and protection to infectious challenge up to 6 mo after immunization. To
define the cellular mechanism by which CpG ODN mediate their adjuvant effects in vivo, the
functional capacity of distinct dendritic cell (DC) subsets was assessed in the lymph nodes (LNs)
of BALB/c mice, 36 h after immunization with the leishmanial antigen (LACK) and CpG
ODN. After this immunization, there was a striking decrease in the frequency of the
CD11c
 
 
 
B220
 
 
 
 plasmacytoid DCs with a proportionate increase in CD11c
 
 
 
CD8
 
 
 
B220
 
 
 
 cells.
CD11c
 
 
 
CD8
 
 
 
B220
 
 
 
 cells were the most potent producers of interleukin (IL)-12 p70 and in-
terferon (IFN)-
 
 
 
, while plasmacytoid DCs were the only subset capable of secreting IFN-
 
 
 
. In
terms of antigen presenting capacity, plasmacytoid DCs were far less efficient compared with
the other DC subsets. To certify that DCs were responsible for effective vaccination, we iso-
lated CD11c
 
 
 
 and CD11c
 
 
 
 cells 36 h after immunization and used such cells to elicit protec-
tive immunity after adoptive transfer in naive, 
 
Leishmania major
 
 susceptible BALB/c mice.
CD11c
 
 
 
 cells but not 10-fold higher numbers of CD11c
 
 
 
 cells from such immunized mice
mediated protection. Therefore, the combination of LACK antigen and CpG ODN adjuvant
leads to the presence of CD11c
 
 
 
 DCs in the draining LN that are capable of vaccinating naive
mice in the absence of further antigen or adjuvant.
Key words: plasmacytoid dendritic cell • Toll-like receptor • 
 
Leishmania major
 
 • vaccine • Th1 cells
 
Introduction
 
Currently there are no uniformly effective vaccines for in-
fections such as 
 
Mycobacterium tuberculosis
 
, malaria, and HIV.
For such infections, the cellular immune response compris-
ing primarily Th1 and CD8
 
 
 
 effector T cells has been
shown to be critical in mediating protection against infec-
tion and/or development of disease (1). Potential difficulties
in generating potent and durable cellular immune responses
in vivo with current vaccines may be due to multiple factors.
First, induction of Th1 cells requires a differentiation process
that involves both Ag stimulation and a Th1-inducing cyto-
kine (2, 3). Second, generation of CD8
 
 
 
 effector T cells re-
quires intracellular processing of Ag, which is most readily
elicited by either live-attenuated or DNA vaccines; how-
ever, live-attenuated vaccines for diseases such as HIV or
 
M. tuberculosis
 
 might be precluded for safety and/or manu-
facturing considerations. In addition, DNA vaccines are far
less potent for inducing immune responses in humans than
in rodents. One recent approach that has shown promise
for generating broad cellular immune responses in vivo is
use of Toll-like receptor (TLR)
 
*
 
 ligands as vaccine adju-
vants (4).
 
Address correspondence to Dr. Robert A. Seder, VRC, NIAID, 40 Con-
vent Dr., Room 40/3512, NIH, Bethesda, MD 20892. Phone: 301-594-
8483; Fax: 301-480-2565; E-mail: rseder@niaid.nih.gov
 
*
 
Abbreviations used in this paper:
 
 CpG ODN, cytosine phosphate guanosine
oligodeoxynucleotide(s); LACK, Leishmania homolog of the receptor for
activated C kinase; SAC, 
 
Staphylococcus aureus
 
 Cowens; TLR, Toll-like
receptor.T
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DCs Mediate Immunity by CpG ODN Immunization
 
At present, there are 10 TLR receptors that respond to
different pathogen-associated molecular patterns (5). One
of the most potent inducers of both innate and adaptive
immunity is mediated through the interaction of cytosine
phosphate guanosine oligodeoxynucleotide (CpG ODN)
with TLR 9 (4, 6). At the initiation of an immune re-
sponse, this interaction leads to increased expression of co-
stimulatory markers such as CD40, CD80, and CD86 and
production of proinflammatory cytokines such as TNF-
 
 
 
,
IL-12, and IL-6 from DCs (7–9). In turn, this facilitates in-
duction of both Th1 and CD8
 
 
 
 T cell responses (10–13).
The physiologic relevance for the immune effects of CpG
ODN in vivo was demonstrated in a mouse vaccine model
of 
 
Leishmania major
 
 infection in which mice immunized
with heat-killed or recombinant leishmanial Ag and CpG
ODN had sustained cellular immune responses and were
protected up to 6 mo after immunization (14). Similarly, in
other studies, vaccination with plasmid DNA encoding
various leishmanial Ag also conferred long-term protection
in a Th1 and CD8
 
 
 
 T cell–dependent manner (15). Thus,
while the aforementioned vaccine studies elucidated the
immune correlates of protection, it remained to be proven
how these different types of vaccine formulations were ini-
tiating such responses at the level of the APC. In this re-
gard, a common feature of plasmid DNA and CpG ODN 
 
 
 
protein vaccines is the ability to transfect (16) and activate
(17) DCs, respectively.
CD11c
 
 
 
 DCs can direct the differentiation of CD4
 
 
 
 T
cells into Th1- or Th2-type cells (18) as well as CD8
 
 
 
 T
cell responses either directly or through cross-priming (19).
The ability of DCs to induce such responses depends on
the specific subset (20), the maturation state (21), and the
conditions of stimulation (22). The great majority of prior
studies analyzing the function of DCs have used either in
vitro–generated or in vitro–cultured bone marrow or
splenic DCs. In addition, characterization of ex vivo-
derived DCs has been limited to nonpathogenic Ag. Thus,
there has not been a systematic study using an entirely in
vivo model in which subsets of DCs from peripheral LNs
were characterized after immunization with a protein de-
rived from a specific pathogen plus CpG ODN for their
ability to present the Ag, secrete cytokines, and mediate
protection to an infectious challenge after adoptive transfer
into naive mice.
The aim of the studies presented here was to determine
the cellular mechanism by which CpG ODN were mediat-
ing protective immunity in vivo when used as a vaccine
adjuvant with a leishmanial Ag. For the leishmanial Ag, we
used the Leishmania homologue of the receptor for acti-
vated C kinase (LACK) protein. LACK is a highly con-
served, immunodominant Ag with a single I-A
 
d
 
–restricted
epitope that has been shown to regulate the natural course
of infection in BALB/c mice and been useful in vaccine
studies for determining the requirements for Th1 and
CD8
 
 
 
 T cells in maintaining long-term memory responses
sufficient to mediate protection (15, 23–25). We hypothe-
sized that DCs from mice immunized with LACK 
 
 
 
 CpG
ODN mediate T cell immunity and protection following
transfer into in naive, 
 
Leishmania major
 
–susceptible BALB/c
mice. The results of this study provide in vivo evidence for
the cellular mechanism by which CpG ODN, which pre-
viously has been shown to have demonstrable adjuvant ac-
tivity, mediates protective immunity in vivo.
 
Materials and Methods
 
Mice.
 
Female BALB/c mice were purchased from the Divi-
sion of Cancer Treatment (National Cancer Institute, National
Institutes of Health). Mice were maintained in the Vaccine Re-
search Center Animal Care Facility (Bethesda, MD) under patho-
gen-free conditions.
 
ODN.
 
For all in vivo immunizations, phosphorothioate-
modified ODN sequence 1826 containing two CpG motifs
(underlined: TCATGACGTTCCTGACGTT) was provided by
Coley Pharmaceutical Group. To assess production of IFN-
 
 
 
under in vitro stimulation, ODN sequence 1585 containing one
CpG motif (underlined: GGGGTCAACGTTGAGGGGGG) was
used. The ODN contained endotoxin levels 
 
 
 
 0.1 EU/mg using
the limulus amebocyte lysis assay (Associates of Cape Cod, Inc.).
 
Immunization.
 
To generate CD11c
 
 
 
 DCs in vivo, naive
BALB/c mice (20–25 mice/group) were injected s.c. in both
hind footpads and flanks with sterile PBS, CpG ODN (25 
 
 
 
g), or
recombinant leishmanial LACK protein (50 
 
 
 
g; Paragon Bioser-
vices, Inc.) with or without CpG ODN. This protein contained
 
 
 
 5.0 EU/dose. Each injection was suspended in sterile PBS and
given in a volume of 50 
 
 
 
l. For some experiments, mice were
vaccinated s.c. in the footpad with 50 
 
 
 
g of LACK protein with
either 25 
 
 
 
g CpG ODN or 1 
 
 
 
g IL-12 protein and boosted 2 wk
later as described previously (26).
 
DC Isolation.
 
At various times after immunization, mice from
each group were killed and their draining popliteal and inguinal
LN passed through a 100-
 
 
 
m cell strainer and digested for 30
min at 37
 
 
 
C by 1 mg/ml collagenase D and 15 
 
 
 
g/ml DnaseI
(Roche). All subsequent procedures were performed on ice in
HBSS. The cells were blocked using 1 mg/ml purified rat IgG or
1:100 2.4G2 Ab (BD Biosciences). CD11c
 
 
 
 cells were positively
selected using magnetized Ab for CD11c (N418; Miltenyi Bio-
tec). After this step, there were 
 
 
 
60% CD11c
 
 
 
 cells. CD11c
 
 
 
DCs were further enriched by staining with FITC-labeled anti-
CD3 and APC-labeled anti-CD19 and sorted for to remove such
cells. After cell sorting, there were 
 
 
 
 95% CD11c
 
 
 
CD3
 
 
 
CD19
 
 
 
cells. To isolate specific DC subsets, CD11c
 
 
 
 cells enriched fol-
lowing magnetic bead separation were stained with FITC-labeled
anti-CD3 and CD19, PE-labeled anti-CD11c (HL3), PerCP-
labeled anti-B220, or APC-labeled anti-CD8 (Ly-2) and sorted
on a FACSVantage™ cell sorter. The resulting population was
consistently 
 
 
 
99% CD11c
 
 
 
, with fewer than 0.5% T cells.
CD11c
 
 
 
 cells were further depleted of CD3
 
 
 
 cells by cell sorting
resulting in a population that was 
 
 
 
90% CD19
 
 
 
 cells.
 
T Cell Proliferation Assay.
 
CD4
 
 
 
 T cell hybridoma LMR 7.5,
detects LACK in the context of MHC class II expressing I-A
 
d
 
(27). To detect the antigen presenting capacity of LACK from
APC immediately ex vivo, 10
 
5
 
 LMR 7.5 hybridoma cells were
cultured with varying numbers of CD11c
 
 
 
 or CD11c
 
 
 
 cells from
mice immunized with PBS, LACK protein, CpG ODN, or
LACK 
 
  
 
CpG ODN or IL-12 protein. Supernatants were har-
vested 24 h later and assayed for IL-2 content by ELISA using
OptEIA kits (BD Biosciences). As a positive control for the abil-
ity of APC to present LACK independent of processing of the
LACK protein in vivo, 10
 
5
 
 LMR 7.5 hybridoma cells were cul-T
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tured with varying numbers of CD11c
 
 
 
 or CD11c
 
 
 
 cells from
naive or immunized mice with 10 
 
 
 
g/ml LACK peptide (amino
acids 156–173; FSPSLEHPIVVSSW). The detection limit for IL-2
production was 3 pg/ml.
 
Adoptive Transfer of CD11c
 
 
 
 and CD11c
 
  
 
Cells.
 
Varying
numbers of CD11c
 
 
 
 DC (10
 
4
 
–5 
 
 
 
 10
 
4
 
) or CD11c
 
 
 
 cells (5 
 
 
 
10
 
4
 
–5 
 
 
 
 10
 
5
 
) from mice immunized with PBS, CpG ODN,
LACK 
 
 
 
 CpG ODN, or IL-12 protein were sorted, resuspended
in sterile HBSS (50 
 
 
 
l), and transferred s.c. into the footpad of
naive BALB/c mice. Mice were boosted 2 wk later in an identi-
cal manner.
 
LACK-specific Production of IFN-
 
 
 
 from BALB/c Mice After
Adoptive Transfer of CD11c
 
 
 
 Cells from Immunized Mice.
 
After
adoptive transfer of CD11c
 
 
 
 DCs into naive BALB/c mice,
LACK-specific production of IFN-
 
 
 
 was assessed from LN be-
fore infection or spleens after infection by culturing 2 
 
 
 
 10
 
5
 
 total
LN or spleen cells/200 
 
 
 
l in flat-bottom 96-well plates with or
without LACK protein (10 
 
 
 
g/ml). Supernatants were harvested
48 or 72 h later and analyzed for IFN-
 
 
 
 content by ELISA using
OptEIA kits. The detection limit for IFN-
 
 
 
 was 62.5 pg/ml.
 
Assessment of Cytokine Production from DCs Isolated After Immuni-
zation.
 
2 d after immunization, total CD11c
 
 
 
 or sorted subsets
of DCs (10
 
4
 
/ml) were isolated from draining LNs, added to 96-
well tissue culture plates, and stimulated in media alone, Staphylo-
coccus aureus Cowens (SAC; 1:1,000) and/or anti-CD40 Ab (1
 g/ml), CpG ODN (5  g/ml), or CpG ODN   anti-CD40 Ab.
Supernatants were collected at 24–48 h for IL-12 p40, p70, and
IL-10 assays. IL-12 p40, p70, and IL-10 were detected using
OptEIA kits. The limit of detection for IL-12 p40 was 125 pg/
ml; for IL-10, 62.5 pg/ml; and for IL-12 p70, 7.8 pg/ml. For de-
tection of IFN- , cells were stimulated with CpG ODN and
poly I:C (25  g/ml). IFN-  was detected using kits purchased
from R&D Systems. The limit of detection was 16 pg/ml.
Characterization of Cell Surface Markers on DCs. After enrich-
ment of CD11c  DCs from mice immunized with LACK, CpG
ODN, both, or neither, cells were stained with the following Ab:
FITC-labeled anti-I-Ad (AMS32.1), anti-CD40 (3/23), anti-
CD80 (16–10A1), anti-CD86 (GL1), APC-labeled CD11b (M1/
70), or Ly-6G/C (RB6–8C5). The relative expression of these
markers was assessed using a FACSCalibur™ flow cytometer
(Becton Dickinson) and analyzed using Flow Jo software.
Infectious Challenge. L.  major clone V1 (MHOM/IL/80/
Friedlin) promastigotes were grown as described previously (26).
Briefly, infective-stage metacyclic promastigotes of L. major were
isolated from stationary cultures (4–5 d old) by negative selection
using peanut agglutinin (Vector Laboratories). BALB/c mice
were infected 2 wk after boost with 105 metacyclic promastigotes.
Parasites were injected into the footpad s.c. contralateral from the
site in which they had received CD11c  or CD11c  cells from
immunized mice. Weekly footpad swelling measurements using a
metric caliper were recorded.
Preparation of Bone Marrow–derived DCs for Detection of LACK-
Specific CD4  and CD8  IFN-  Responses. To measure LACK-
specific T cell immune responses after adoptive transfer, we used
normal bone marrow–derived DCs from BALB/c mice (1.2  
106) alone or pulsed with LACK protein anti-CD40, and CpG
ODN. These were cocultured for 2 h with total splenocytes (6  
106) from BALB/c mice that had received CD11c  or CD11c 
cells from mice immunized with LACK   CpG ODN. BFA (10
 g/ml) was then added and 4 h later cells were fixed, permeabi-
lized, and stained with FITC-labeled anti-CD3  (145–2C11),
PE-labeled anti-CD8  (Ly-2), PerCP-labeled anti-CD4 (L3T4),
or APC-labeled anti-IFN-  (XMG1.2). The frequency of CD4 
and CD8  T cells producing IFN-  was assessed after collecting
300,000 total events in each group.
Results
CD11c  Cells From Mice Immunized With LACK   CpG
ODN Present Ag to LACK-Specific CD4  T Cells. To de-
termine the mechanism by which CpG ODN confers pro-
tection as a vaccine adjuvant with the leishmanial LACK
protein, we first assessed the capacity of various populations
of APCs to present LACK to a LACK-specific CD4  T
cell hybridoma (LMR 7.5) following immunization (27).
Naive BALB/c mice were immunized s.c. with PBS, CpG
ODN alone, or LACK   CpG ODN. Draining LNs were
then harvested at various times post immunization, and
CD11c  and CD11c  cells were isolated by cell sorting
and added to LMR 7.5 cells to determine their capacity to
present LACK Ag. As shown in Fig. 1 A, CD11c  cells
(104) isolated 2 d after immunization with LACK protein
or LACK   CpG ODN induced substantial amounts of
IL-2 from the LMR 7.5 cells. Moreover, as few as 103
CD11c  cells from such immunized mice were sufficient
to induce IL-2 from the LMR 7.5 cells (Fig. 1 C). In con-
trast, CD11c  cells from mice immunized with PBS or
CpG ODN alone did not induce any IL-2 production
from LMR 7.5 cells. These data demonstrate that only
CD11c  cells from mice immunized with LACK   CpG
ODN have acquired the capacity in vivo to present LACK
to the LMR 7.5 cells. When assessed 7 d after immuniza-
tion, there was no detectable IL-2 produced by the LMR
7.5 cells from CD11c  cells in any of the groups (Fig. 1 B).
Consequently, for the remainder of the experiments shown
below, CD11c  cells were isolated from draining LN 36–
48 h after immunization.
In comparing the efficiency of antigen presentation be-
tween CD11c  DCs and CD11c  cells ( 90% B cells),
while the same number of CD11c  cells (104) from mice
immunized with LACK   CpG ODN did not induce any
IL-2 from LMR 7.5 cells (unpublished data), a small
amount of IL-2 was induced from LMR 7.5 cells using 105
CD11c  cells (Fig. 1 A).
CD11c  Cells from Mice Immunized with LACK and CpG
ODN Produce IL-12. Cytokines released from CD11c 
cells have a strong influence on the CD4  T cell response
(2, 28). CD11c  cells isolated 2 d after immunization with
PBS, CpG ODN, or LACK   CpG ODN were analyzed
for production of IL-12 p40, p70, and IL-10 after restimula-
tion in vitro. As shown in Fig. 2 A, CD11c  cells from
mice immunized with CpG ODN or LACK   CpG ODN
had significant production of IL-12 p40 in response to SAC,
anti-CD40, or both (P   0.05). There was no detectable
IL-12 p40 from CD11c  cells from any of the immunized
groups (data not shown). IL-12 p70 was only detected from
mice immunized with LACK   CpG ODN (Fig. 2 B; P  
0.05). Last, there were no significant differences in IL-10
production in response to SAC   anti-CD40 stimulation
between any of the immunized groups (Fig. 2 C). Together
with the previous figure, these data show that only mice im-T
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munized with both LACK protein and CpG ODN are able
to present Ag and secrete IL-12 p70.
In this experiment, cytokine production from CD11c 
cells from mice immunized with LACK   IL-12 protein
was also determined. This additional group was of interest
because naive BALB/c mice vaccinated with this regimen
are protected when mice are infected shortly after immuni-
zation (26, 29). Therefore, cells from such immunized mice
can be used to compare whether the mechanism of protec-
tion vis a vis CD11c  cells was similar using IL-12 protein
as an adjuvant compared with CpG ODN. As shown in
Fig. 2 A, production of IL-12 p40 from CD11c  cells from
LACK   IL-12–immunized mice was demonstrably less
than from CD11c  cells from LACK   CpG ODN-immu-
nized mice.
The Frequency of DC Subsets Is Substantially Altered After
Immunization. Previous studies have shown that at least
five distinct subsets can be identified in LN of naive mice
(22, 30). Thus, we determined the frequency and func-
tional capacity of subsets of CD11c  cells based on ex-
pression of CD8 and B220. These markers allowed for
the historical classification of lymphoid (CD11c CD8 
B220 ), myeloid (CD11c CD8 B220 ), and plasmacytoid
(CD11cintB220 ) DCs. The frequency of CD11c  cells
expressing CD8 and B220 from LN of naive (no injection)
and immunized mice from a representative experiment is
shown in Fig. 3 A. Table I shows the percentage of these
three populations of CD11c  DCs from naive and immu-
nized mice combined from four independent experiments.
It was notable that the majority of CD11c  cells in unim-
munized naive BALB/c mice comprise B220  (56.55%  
4.5%) and CD8  (39.80%   3.9%) cells. Moreover,
there is a significant decrease in the percentage of
CD11c B220  cells after injection with PBS, LACK pro-
tein, or LACK protein   CpG ODN (P   0.05). This de-
crease is accompanied by a proportional increase in the
percentage of CD11c CD8  cells. In terms of total num-
ber of DC subsets following immunization, while mice
immunized with CpG ODN   LACK protein had a 2–3-
fold increase in the number of total lymph node cells as
well as CD11c  cells at day 2 after immunization there was
no appreciable change in the number of lymph node or
CD11c  cells after injection with PBS or LACK protein
alone. In addition, the change in the frequency of CD11c 
DC subsets after sterile PBS immunization was a consistent
Figure 1. LACK Ag-presenting
capacity of CD11c  and CD11c 
cells derived in vivo after immuniza-
tion. BALB/c mice (20 mice per
group) were injected s.c. into four
separate sites with PBS, CpG ODN,
LACK, or LACK   CpG ODN.
CD11c  and CD11c cells were iso-
lated 2 d (A) or 7 d (B) later from
draining LN. CD11c  (104; A and
B) or CD11c- (105; A and B) were
cocultured with LMR 7.5 hybridoma
cells (105) for 24 h. IL-2 content was
assessed from the supernatants from
triplicate wells. (C) In a separate
experiment, varying numbers of
CD11c  cells from mice immunized with LACK   CpG ODN were added to LMR 7.5 cells and IL-2 content assessed. Results are expressed as
geometric mean   SEM and are representative of four individual experiments.
Figure 2. IL-12 and IL-10
production from CD11c  and
CD11c  cells after immuniza-
tion. CD11c  (104) and CD11c 
(104) cells from BALB/c mice
immunized with PBS, CpG, or
LACK   CpG ODN, or IL-12
were isolated from draining LN
2 d after immunization and cocul-
tured with nothing, SAC, anti-
CD40, or both for 24 h. IL-12
p40 (A), IL-12 p70 (B), and IL-10
(C) were measured by ELISA.
Results are expressed as geo-
metric mean   SEM and are
representative of four individ-
ual experiments. * indicates P  
0.05 for mice immunized with
LACK    CpG ODN as com-
pared with PBS-immunized or
LACK protein-immunized mice.T
h
e
 
J
o
u
r
n
a
l
 
o
f
 
E
x
p
e
r
i
m
e
n
t
a
l
 
M
e
d
i
c
i
n
e
285 Shah et al.
finding and likely reflects inflammation association with
the s.c. injection itself.
Differential Expression of Cell Surface Markers on Subsets of
CD11c  Cells After Immunization. The expression of cell
surface molecules on the DC subsets was determined from
LN cells of naive or immunized mice. As shown in Fig. 3
B, both CD11c CD8  and CD11c CD8  cells had in-
creased expression of MHC class II, CD40, and CD86
compared with CD11c B220  cells from naive or mice
immunized with CpG ODN   LACK. In terms of other
markers, Ly-6G/C, a marker used to define murine plas-
macytoid DCs (31), was present on all CD11c B220  but
not CD8  or CD8  cells from naive mice or mice immu-
nized with PBS or LACK protein. Of note was that ex-
pression of Ly-6G/C was decreased on CD11c B220 
cells after immunization with CpG ODN   LACK pro-
tein. In contrast, while expression of CD11b was low on
CD11c B220  cells from naive mice or after PBS or
LACK protein immunization, it was strongly enhanced af-
ter immunization with CpG ODN   LACK protein.
Subsets of CD11c  DC from Immunized Mice Have Distinct
Ag-presenting Capability. To assess whether differential ex-
pression of MHC class II and costimulatory molecules al-
tered Ag-presenting capacity, sorted DC subsets were iso-
lated after immunization in vivo and used to stimulate
LMR 7.5 cells. As shown in Fig. 4, all three subsets of
CD11c  cells were able to induce IL-2 secretion from
LMR 7.5 cells if mice were immunized with LACK  
CpG ODN. There was a modest decrease in the produc-
tion of IL-2 from LMR 7.5 cells from both CD8  and
CD8 B220  DCs in mice immunized with both LACK
protein and CpG ODN compared with LACK protein
alone. This was a consistent finding in other experiments
and may reflect maturation of the DCs in vivo by the CpG
ODN. In comparing LACK presentation among the other
subsets of CD11c  cells, CD11c B220  cells were far less
efficient on a per-cell basis from cells derived ex vivo after
immunization with LACK   CpG ODN. Moreover, such
cells were less potent at inducing IL-2 production even
when LACK peptide was added in vitro compared with
the other subsets of DCs (P   0.05).
Subsets of CD11c  Cells from Immunized Mice Have Dis-
tinct Cytokine-producing Capacity. The production of cyto-
kines such as IL-12 (20) and IFN-  (31–33) from DC
subsets can be strongly influenced by the conditions of
stimulation. As shown in Fig. 5 A, CD11c CD8  DCs
were the most potent producers of IL-12 p40 from all im-
Figure 3. Frequency of DC
subsets and their expression of
cell surface markers from LN af-
ter immunization. (A) CD11c 
DCs from draining LNs of naive
(no injection) and or mice im-
munized with PBS, CpG ODN,
or LACK protein   CpG ODN
mice were enriched as described
in the methods and stained with
antibodies against CD11c, CD8
and B220. Cells were gated on
CD11c  cells and the percent-
age of CD11c CD8 B220 ,
CD11c CD8 B220 , and
CD11c B220  is shown. (B)
Expression of cell surface mark-
ers was analyzed on subsets of
CD11c  DCs based on expres-
sion of CD8 and B220. Light
blue, no injection; black, PBS;
blue, CpG ODN; green, LACK;
red, LACK   CpG ODN. Data
are representative of three inde-
pendent experiments.
Table I. Frequency of DC Subsets After Immunization
DC
subset
No 
injection PBS
CpG
ODN LACK
LACK  
CpG ODN
B220  56.6   4.5 36.6   5.6 16.4   6.6 26.5   7.1 17.7   9.0
CD8  3.7   0.4 4.0   1.8 4.8   2.9 4.7   2.1 6.7   5.6
CD8  39.8   4.0 58.8   5.0 78.8   5.4 68.9   8.7 75.7   9.3
The frequency of CD11c CD8 B220 , CD11c CD8 B220 , and
CD11c B220  cells from draining LN of naive and immunized mice
was determined from four independent experiments. Results are
expressed as geometric mean   SEM: P   0.05 when comparing any of
the immunization groups to naive mice; P   0.05 when comparing
mice immunized with LACK protein, CpG ODN, or both with PBS-
injected mice.T
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munization groups compared with the other DC subsets
(P   0.05). Immunization with both LACK protein and
CpG ODN had the most dramatic effect on production of
IL-12 p40 from all subsets of DCs and was especially no-
table for CD11c CD8  DCs. IL-12 p70 was detected
from  CD11c CD8  and CD11c B220  cells but not
CD11c CD8  cells from mice immunized with LACK  
CpG ODN (Fig. 5 B). These data clearly show that a TLR
stimulus coupled with a signal mediated by protein immu-
nization (i.e., CD40 ligand) is optimal for IL-12 p70 from
CD11c CD8  (34) and plasmacytoid DCs (35, 36). Finally,
as DC production of IFN-  (37) and IFN-  (31–33) could
influence Th1 and CD8  T cell responses, the capacity of
DCs to secrete such cytokines was assessed. CD11c CD8 
cells from mice immunized with LACK   CpG ODN was
induced to secrete IFN- , whereas production of IFN- 
was only produced by CD11c B220  DC (Fig. 5 C).
CD11c  Cells from Immunized Mice Induce LACK-specific
Production of IFN-  in Naive BALB/c Mice After Adoptive
Transfer. The remaining experiments focused on the
ability of CD11c  cells generated in vivo by immunization
to elicit immunity and protection after adoptive transfer
into naive BALB/c mice that are susceptible to L. major
infection. CD11c  cells and CD11c  cells were sorted
from the various groups of immunized mice and injected
into naive BALB/c mice. As shown in Fig. 6 A, only
CD11c  cells from mice immunized with LACK   CpG
ODN induced production of IFN-  from lymph node cell
stimulated with LACK protein in vitro (P   0.05). Thus,
Th1 cells are induced in naive BALB/c mice after adop-
tive transfer of CD11c  cells from LACK   CpG ODN
immunized mice.
CD11c  Cells from Immunized Mice Confer Protection to
Naive BALB/c Mice After Challenge with L. major. The
susceptibility of BALB/c mice to L. major infection is me-
diated by a Th2 response to the immunodominant LACK
Ag (23–25). The data that CD11c  cells from mice immu-
nized with LACK   CpG ODN induced Th1 cells fol-
lowing transfer into naive BALB/c mice suggested that
such cells might be sufficient to mediate protection to chal-
lenge with L. major. CD11c  and CD11c  cells from mice
immunized with LACK, CpG ODN, or LACK   CpG
Figure 4. LACK Ag-pre-
senting capacity of CD11c 
DC subsets isolated directly
from LNs after immuniza-
tion.  Sorted CD11c CD8 ,
CD11c CD8 B220 , and
CD11c CD8 B220  (104
cells) were cultured with LMR
7.5 cells (105) for 24 h with or
without LACK peptide (10  g/
ml) and IL-2 content assessed.
Results are expressed as geomet-
ric mean   SEM. * indicates
P    0.05 from CD11c CD8 
and CD8  as compared with
that from CD11c B220  DCs.
Figure 5. Production of IL-12,
IFN- , and IFN-  from CD11c 
DC subsets after immunization.
Sorted CD11c CD8 B220 ,
CD11c CD8 B220 , and
CD11c B220  (5   103) cells
were isolated from draining LN
2 d after immunization with PBS,
CPG ODN, or LACK   CpG
ODN and cocultured with noth-
ing, anti-CD40 (1  g/ml), CpG
ODN (5  g/ml), or both. (A)
IL-12 p40 was measured from all
immunized groups. IL-12 p70
(B) and IFN-  (B) were only de-
tected from mice immunized
with LACK   CpG ODN. (C)
IFN-  was measured by ELISA
from CD11c B220  cells in re-
sponse to stimulation with CpG
ODN 1585 and Poly I:C. Results
are expressed as geometric mean  
SEM and are representative of
three independent experiments.T
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ODN were adoptively transferred twice at 2 wk intervals
in one footpad and then challenged 2 wk later with L. ma-
jor in the opposite footpad. As an assessment of disease pro-
gression, the footpad size was followed over a period of 6
wk, at which point the experiment was terminated due to
ulceration and necrosis of the footpads in all groups that
were not able to control infection. As shown in Fig. 6 B,
naive BALB/c mice that received 5   104 CD11c  cells
from mice immunized with LACK   CpG ODN were
able to control infection. Moreover, even 104 of such
transferred cells also conferred some control of infection. In
contrast, CD11c  cells from the other immunized mice
(CpG ODN or LACK alone) or CD11c  cells from all
groups of immunized mice had no ability to control infec-
tion (Fig. 6 C). In addition, even 5   105 CD11c  cells
from mice immunized with LACK   CpG ODN did not
exert any control of infection. Finally, it is well established
that the degree of footpad swelling is a good correlate for
the parasite load in BALB/c mice after infection. In this re-
gard, in other related experiments, we did observe a 3–10-
fold decrease in parasite load in mice that received CD11c 
cells compared with CD11c  cells from leishmanial pro-
tein   CpG ODN immunized mice (unpublished data).
These data clearly show that the mechanism by which CpG
ODN mediates protection as an immune adjuvant in this
model is through CD11c  cells.
In Fig. 2, we showed that CD11c  cells from mice im-
munized with LACK and the adjuvant IL-12 (LACK  
IL-12) had relatively modest production of IL-12 after re-
stimulation in vitro. Moreover, CD11c  cells from mice
Figure 6. Immunogenicity
and protection induced by
CD11c  DCs from immunized
mice. CD11c  and CD11c  cells
(105 cells) from immunized mice
were transferred by s.c. injection
into naive BALB/c mice (A). 4 d
later, draining LN were re-
moved, restimulated with LACK
protein, and production of IFN- 
assessed from supernatants by
ELISA. Results are expressed as
geometric mean   SEM and are
representative of three indepen-
dent experiments. * indicates
P   0.05 for cells of mice that
received CD11c  cells from
LACK    CpG ODN-immu-
nized mice compared with all
other groups. (B) Varying num-
bers (5   104 cells for all groups
except where noted) of CD11c 
or CD11c  cells from mice im-
munized with CpG ODN or
LACK   CpG ODN or IL-12
protein were adoptively trans-
ferred s.c. into the footpad of na-
ive BALB/c mice. Mice were
boosted 2 wk later with the same
regimen and then challenged
with 105  L. major metacyclic
promastigotes in the opposite
footpad from which they re-
ceived the cells from the immu-
nized mice. Control of infection
was assessed by measuring the di-
ameter of the footpad lesions.
Results are representative of
three separate experiments. To
assess immune responses post in-
fection, splenocytes (2   105
cells/200  l) from infected mice
that received CD11c  or
CD11c  cells from immunized
mice (C) or from naive BALB/c
mice vaccinated with LACK  
IL-12 or CpG ODN (D) were
stimulated with LACK protein
(10  g/ml) for 48 h and production of IFN-  assessed from supernatants. Results are the geometric mean of three replicate wells. Error bars represent the
SEM. * indicates P   0.05 for cells of mice that received CD11c  cells from LACK   CpG ODN-immunized mice compared with all other groups.T
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immunized with LACK   IL-12 did not confer any pro-
tection following adoptive transfer into naive BALB/c
mice (Fig. 6 B). As a positive control in the same experi-
ment, naive BALB/c mice vaccinated with LACK   IL-12
were able to control infection following challenge (data not
depicted). Thus, the mechanism that leads to development
of protective immune responses appears to be different by
LACK   IL-12 versus CpG ODN vaccination.
As an immune correlate of protection after infection,
LACK-specific production of IFN-  was determined 6 wk
after infection in naive BALB/c mice that received
CD11c  or CD11c  cells from mice immunized with
CpG ODN, LACK protein, or LACK   CpG ODN. As
shown in Fig. 6 C, IFN-  was only detected from mice
that received CD11c  cells from LACK   CpG ODN-
immunized mice. Moreover, the amount of IFN-  in-
duced from these mice also correlated with the number of
transferred cells. Production of IFN-  was also assessed
from naive BALB/c mice vaccinated with LACK   IL-12
or CpG ODN after infection (Fig. 6 D). The amount of
IFN-  from mice vaccinated with LACK   CpG ODN
was comparable to that from mice receiving CD11c  cells
from mice immunized with the combination (Fig. 6 D)
while mice vaccinated with LACK   IL-12 had substantial
production of IFN- , consistent with the potent short-
term induction induced by this vaccine.
CD11c  Cells from Immunized Mice Induce Th1 and CD8 
T Cell Responses After Adoptive Transfer and Infection with L.
major. Vaccine elicited protection by leishmanial anti-
gen plus CpG ODN against L. major requires both Th1
and CD8  T cells (14). As shown above, CD11c  cells
from LACK  CpG ODN immunized mice induced
Th1 responses after transfer into naive BALB/c mice.
Thus, we determined whether CD11c  cells generated
in vivo from LACK   CpG ODN-immunized mice
could also induce LACK-specific CD8  T cells after
adoptive transfer into naive mice. To assess this, spleen
cells of mice that had received CD11c  or CD11c 
cells from the indicated groups of immunized mice
were harvested 3 wk after infection with L. major and
stimulated in vitro with fresh bone marrow DCs pulsed
with LACK protein and matured with anti-CD40 and
CpG ODN. As shown in Fig. 7, both CD4 and CD8 
IFN- –producing cells were only detected from mice
which received CD11c  cells from mice immunized
with LACK   CPG ODN.
Discussion
CpG ODN has potent effects in linking innate and adap-
tive immune responses in vivo when used as a vaccine ad-
juvant. In this report, to address the mechanism by which
CpG ODN were responsible for vaccine protection in
vivo, we performed an extensive functional analysis of dis-
tinct DC subsets from draining LN of mice immunized
with LACK   CpG ODN. We show that DC from mice
immunized with LACK   CpG ODN were capable of
presenting antigen, secreting IL-12 p70, IFN- , and IFN- 
and after adoptive transfer were sufficient to mediate pro-
tective immunity in naive BALB/c mice after challenge
with L. major.
In characterizing the number and frequency of DC af-
ter immunization, we observed a decrease in the relatively
high frequency of CD11c B220  cells in BALB/c (38)
mice in response to injection of PBS itself, LACK pro-
tein, and CpG ODN. The change in the frequencies of
DC subsets was observed in mice in which the total num-
ber of CD11c  cells was not altered by immunization
with PBS or LACK or was increased  2–3-fold after im-
munization with CpG ODN. There are several possible
mechanisms to account for these changes in the respective
numbers of DC subsets after immunization. First, the in-
flammatory responses induced by immunization could
lead to the selective death and/or migration of plasmacy-
toid DCs in vivo compared with the other subsets. While
CpG ODN can help maintain survival of plasmacytoid
DCs in vitro (30, 38, 39), it is not clear whether CpG
ODN have similar effects in vivo at least over the short-
time period in which we evaluated this. Another possibil-
ity is that the s.c. immunization causes migration from the
skin into the LN of Langerhans cells that have the effect
of enriching the number of CD11c CD8 B220  cells. A
final mechanism involves alterations in lineage differentia-
tion and commitment and whether plasmacytoid DCs de-
velop a phenotype consistent with a different subset of
DCs after immunization. At present there is no evidence
from our data or previous studies to support such flexibil-
ity of plasmacytoid DCs in developing into other types of
DCs (39–41). Whether one or a combination of these
mechanisms explains the change in the frequency of DC
subsets after immunization with CpG ODN remains an
open question.
Figure 7. Frequency of LACK-specific CD4  and CD8  IFN- –pro-
ducing cells from BALB/c mice after transfer of CD11c  DCs and infec-
tion. Pooled spleen cells from BALB/c mice (n   3) that received two
immunizations with sorted CD11c  DCs from BALB/c mice immunized
with LACK   CpG ODN were harvested 3 wk after infection with L.
major. Spleen cells were cultured (6   106) with bone marrow–derived
DCs from BALB/c mice (1.2   106) with or without exposure to LACK
protein, anti-CD40, and CpG ODN stimulation. Cells were processed
and stained as described to enumerate the frequency of LACK-specific
CD4  and CD8  T cell IFN-  responses. Numbers represent the per-
centage of CD4  or CD8  T cells positive for IFN- . * indicates P  
0.05 for cells of mice that received CD11c  cells from LACK   CpG
ODN-immunized mice compared with all other groups.T
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In assessing the antigen presenting capacity of DCs after
immunization, we found that CD11c  cells capable of pre-
senting LACK to the LACK-specific LMR 7.5 hybridoma
could be detected from draining LN as early as 18 h after
immunization, which peaked at 36–48 h and was not
present at 7 d. The kinetics of the response are consistent
with previous reports showing intimate contact of T cells
and DCs occurring within hours after antigenic challenge
(42) that begin to dissociate after 36–48 h (43). These data
suggest that CD11c  cells capable of presenting LACK
died, migrated, and/or lost expression of LACK/MHC
complexes on their cell surface from LN 2 d after immuni-
zation. In terms of the relative potency of Ag presentation,
both CD11c CD8  and CD8  cells were substantially
more efficient than CD11c B220  DCs in presenting Ag
immediately ex vivo. Thus, due to the relatively high fre-
quency of CD11c CD8  cells in the LN; they would
likely have the most prominent role in initiating T cell im-
mune responses (44). These data are consistent with the
finding that only CD11c CD11b CD8  DCs are capable
of presenting LACK Ag after infection with L. major (44a).
In contrast, the relative deficiency of B220  cells for Ag
presentation compared with the CD8  and CD8  might
involve a qualitative difference in Ag processing or presen-
tation resulting in diminished ability to assemble peptide–
MHC complexes (45). Moreover, CD11c B220  DCs
have a demonstrable decrease in expression of MHC class
II and other costimulatory markers (31, 38, 45). Finally, the
high sensitivity of the LMR 7.5 hybridoma for detecting
LACK Ag might have overestimated even the relatively
limited Ag-presenting capacity of CD11c B220  cells. In
this regard, recent reports showing that freshly isolated na-
ive or virally exposed splenic plasmacytoid DCs were un-
able to induce proliferation of naive CD4  T cells (45, 46)
but could promote expansion of previously activated T
cells (45) might be analogous to our studies showing that
plasmacytoid DCs induce low but detectable IL-2 produc-
tion from a T cell hybridoma. While these data do not ab-
solutely preclude a role of LN plasmacytoid DCs in Ag
presentation with protein and CpG ODN immunization in
vivo, they suggest that the relatively high frequency of such
cells in normal LN of BALB/c mice might be more in-
volved in maintaining tolerance in their steady-state and
upon activation provide stimulation through their produc-
tion of cytokines.
In addition to Ag presentation, DCs strongly influences
the qualitative and quantitative aspects of cellular immune
responses. CD11c CD8 B220  DCs were the most po-
tent producers of IL-12 p40 and p70 (20) and the only DC
subset able to secrete IFN-  after immunization with
LACK   CpG ODN. Plasmacytoid DCs also produced
IL-12 p70 and IFN-  after immunization. Thus, due to the
relatively low frequency of CD11c  CD8 B220  DCs in
LN of naive or immunized mice and the limited capacity of
plasmacytoid DCs for Ag presentation, these particular sub-
sets of DCs through production of IL-12 p70, IFN- , and
IFN-  likely mediate their effects by providing a favorable
milieu to activate Th1 (28, 47, 48) and CD8  T cell (49)
responses. A final point is whether the effects of CpG
ODN on DC subsets are direct and/or indirect. In mice, it
has recently been shown that CD8  , CD8   and plasma-
cytoid DCs derived from spleens had comparable mRNA
expression for TLR-9 and all could be induced to secrete
IL-12 p40 after stimulation with CpG ODN (46, 50).
These data are consistent with our findings that CpG ODN
directly activates all the DC subsets studied here with in-
duction of inflammatory cytokines and up-regulation of
costimulatory molecules. In addition, CpG ODN likely
have substantial indirect effects for generating adaptive cel-
lular immune responses. Such indirect effects could be
through IL-12 and IFN-  inducing NK production of
IFN-  which would enhance Th1 responses. In addition,
IFN-  induced from plasmacytoid DC can also enhance
the maturation of other DC subsets (51). Thus, the effect of
CpG ODN on DC subsets and T cell responses involves
both direct and indirect mechanisms. In summary we spec-
ulate that there is a cooperative effect with potential spe-
cialization of the various DC subsets in vivo for inducing a
functional cellular immune response. For the model studied
here, CD11c CD8  would be primarily involved in anti-
gen presentation, while CD11c CD8 B220  and plasma-
cytoid DCs provide a favorable cytokine milieu for en-
hancing adaptive immune responses.
The demonstration that in vivo-derived LN CD11c 
DCs after immunization with LACK   CpG ODN are
sufficient to mediate immunity and protection against an
intracellular infection provides strong evidence for how
CpG ODN mediate their effects as an adjuvant in vivo.
With regard to how the transferred CD11c  DCs mediates
their effects in vivo, there are two potential mechanisms.
First is the importance of IL-12 from the transferred
CD11c  cells from immunized mice in priming Th1 re-
sponses in the recipient mice. It has been shown recently
that wild-type but not IL-12–deficient Langerhans cells
pulsed in vitro with a variety of leishmanial Ag including
LACK could confer protection (52). Thus, it is likely that
IL-12 would be required from the transferred CD11c 
cells. The second consideration is whether the induction of
Th1 and/or CD8  T cell responses after adoptive transfer
of cells from mice immunized with LACK protein   CpG
ODN into naive mice is direct and/or indirect via cross-
priming from recipient cells.
To conclude, these studies focused exclusively on pe-
ripheral LN DCs. While there is heterogeneity among DC
populations and function between LN, spleen, and bone
marrow–derived DCs, we believe these results examining
how peripheral LN DCs are altered by s.c. immunization
has direct relevance for vaccine design in humans. In this
regard, despite the broad distribution of TLR-9 expression
amongst mouse DC subsets (50), its expression in primates
and humans is limited to B cells and plasmacytoid DCs
(53). Thus for humans, the antigen presenting capacity and
production of cytokines of plasmacytoid DCs in vivo will
largely determine whether CpG ODN alone are effective
vaccine adjuvants for inducing adaptive cellular immune
response in people. If indeed such cells are not optimal forT
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antigen presentation as in the mouse, combination strate-
gies aimed at targeting additional DC populations using
other TLR ligands or combinations of TLR ligands might
be necessary for efficient generation of cellular responses in
humans. Nevertheless, this report showing that freshly iso-
lated CD11c  but not CD11c  cells from mice immunized
using CpG ODN as an adjuvant are capable of transferring
protective immunity should provide a more targeted and
rational approach to vaccine development for diseases re-
quiring cellular immune responses.
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